Data from a recent phase II study (NCT02804763) demonstrated that dapirolizumab pegol (a pegylated Fab anti-CD40L) treatment in active SLE patients was associated with numerically higher response rates and greater improvement in several clinical outcome measures compared with placebo, but the difference in primary efficacy endpoint of British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response between the two groups did not reach statistical significance93. The gene discussed is CD40LG; the disease is systemic lupus erythematosus.